Major Players Swap Positions Among Industry Top 50
Key Developments Lead To Ups And Downs In The Middle Of Our Ranking
Executive Summary
The second part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies sees a number of major firms sliding up and down the table.
You may also be interested in...
Alkem Looks To Biosimilars With Enzene’s Teriparatide In India
With the approval in India of its Enzene subsidiary’s version of teriparatide, Alkem is setting its sights on the biosimilars market.
Accord Seeks To Capitalize On Portfolio And Partnerships
Accord expects to maintain its historically high growth rates through a “holistic” approach to medicines that covers generics and biosimilars alongside more innovative products, with recent marketing alliances in Europe playing into the firm’s ambitions in the CNS area.
Hikma Is Keeping On Top Of COVID ‘Rollercoaster’
Careful supply-chain planning and an agile, flexible approach to manufacturing have been key in helping Hikma to stay on top of the “rollercoaster ride” provided by the COVID-19 pandemic in 2020 so far, according to CEO Siggi Olafsson.